Spots Global Cancer Trial Database for Interferon Alfa (IFN-Alpha-1b) in Renal Cancer With Metastatic Kidney Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Interferon Alfa (IFN-Alpha-1b) in Renal Cancer With Metastatic Kidney Cancer

Official Title: A Phase II Trial of Interferon Alpha-1b (IFN Alpha-1b) in Patients With Metastatic Clear Cell Renal Carcinoma

Study ID: NCT00278174

Conditions

Kidney Cancer

Interventions

recombinant interferon alpha-1b

Study Description

Brief Summary: RATIONALE: Interferon alfa may interfere with the growth of tumor cells and slow the growth of kidney cancer. PURPOSE: This phase II trial is studying how well interferon alfa works in treating patients with metastatic kidney cancer.

Detailed Description: OBJECTIVES: Primary * Determine the objective response rate in patients with metastatic renal clear cell carcinoma treated with interferon alfa-1b. Secondary * Determine the toxicity of this drug in these patients. OUTLINE: This is an open-label study. Patients receive interferon alfa-1b subcutaneously daily. Treatment continues in the absence of unacceptable toxicity or disease progression. After completion of study treatment, patients are followed periodically. PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.